Nabla Bio Raised $26M Series By Radical Ventures

Nabla Bio Raised $26M Series By Radical Ventures

Massachusetts-based, Nabla Bio, a health tech company that develops wet-lab technologies with AI integration raised $26 million led by Radical Ventures in a Series A round.

The round was actively participated by existing investors. Nabla Bio also done strategic collaborations with big companies such as Takeda, Bristol Myers Squibb Company, and AstraZeneca.

Nabla Bio Raised $26M Series A

Co-founders Nabla Bio, Frances Anastassacos, and Surge Biswas said that the raised funds will enable them to work on advanced AI integration with lab-tech that automatically precise drugs and checks the high-throughput measurement.

Nabla Bio AI is initially focused on antibodies targeting multipass membrane proteins. Moreover, to maximize Nabla Bio’s growth they are partnering with pharmaceutical companies that track their drug development to expand growth.

CEOP Surge said that these types of collaborations offer valuable insights into disease and AI development. It also helps us in Research & Development enabling Nabla Bio to accelerate growth sustainably.

Also Read: Together AI Raised $102.5M Series A

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *